Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges

Bibliography

• El-Sadr WM, Lundgren JD, Neaton JD, CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Nelson M, Lazzarin A, MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359:1442-55
   PubMed Web of Science ®Google Scholar
• Wilken T, Lalama C, McKinnon J, Maraviroc intensification for suboptimal CD4+ cell response despite sustained virologic suppression: ACTG 5256 [abstract 285]. 17th CROI
   Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700
   PubMed Web of Science ®Google Scholar
• Tagat JR, McCombie SW, Nazareno D, Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-(2-methoxy-1(R)-4-trifluoromethyl)-phenyl)ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004;47:2405-8
   PubMed Web of Science ®Google Scholar
• Sattentau QJ, Moore JP. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-15
   PubMed Web of Science ®Google Scholar
• Trkola A, Dragic T, Arthos J, CD4- dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996;384:184-7
   PubMed Web of Science ®Google Scholar
• Wu L, Gerard NP, Wyatt R, CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-83
   PubMed Web of Science ®Google Scholar
• Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997;89:263-73
   PubMed Web of Science ®Google Scholar
• Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4
   PubMed Web of Science ®Google Scholar
• Huang CC, Lam SN, Acharya P, Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007;317:1930-4
   PubMed Web of Science ®Google Scholar
• Huang CC, Tang M, Zhang MY, Structure of a V3-containing HIV-1 gp120 core. Science 2005;310:1025-8
   PubMed Web of Science ®Google Scholar
• Rizzuto C, Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses 2000;16:741-9
   PubMed Web of Science ®Google Scholar
• Rizzuto C, Wyatt R, Hernandez-Ramos N, A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998;280:1949-53
   PubMed Web of Science ®Google Scholar
• Wyatt R, Kwong PD, Desjardins E, The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-11
   PubMed Web of Science ®Google Scholar
• Dragic T, Trkola A, Thompson DA, A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-44
   PubMed Web of Science ®Google Scholar
• Kondru R, Zhang J, Ji C, Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008;73:789-800
   PubMed Web of Science ®Google Scholar
• Maeda K, Das D, Ogata-Aoki H, Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 2006;281:12688-98
   PubMed Web of Science ®Google Scholar
• Tsamis F, Gavrilov S, Kajumo F, Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003;77:5201-8
   PubMed Web of Science ®Google Scholar
• Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease. Annu Rev Immunol 1999;17:657-700
   PubMed Web of Science ®Google Scholar
• Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006;296:815-26
   PubMed Web of Science ®Google Scholar
• Lusso P. HIV and the chemokine system: 10 years later. EMBO J 2006;25:447-56
   PubMed Web of Science ®Google Scholar
• Schurmann D, Fatkenheuer G, Reynes J, Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007;21:1293-9
   PubMed Web of Science ®Google Scholar
• Sansone A, Keung A, Caceres M, Rising multiple-dose assessment of Sch 417690 – Similar safety, tolerability, and pharmacokinetics (PK) in uninfected and HIV-infected adults [abstract A-33]. 45th ICAAC 2005
   Google Scholar
• Keung A, Sansone A, Caceres M, Effect of food on bioavailability of Sch 417690 in healthy volunteers [abstract A-1200]. 45th ICAAC 2005
   Google Scholar
• Crawford KW, Li C, Keung A, Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211). J Acquir Immune Defic Syndr 2010;53:598-605
   PubMed Web of Science ®Google Scholar
• Ghosal A, Ramanathan R, Yuan Y, Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 2007;35:2186-95
   PubMed Web of Science ®Google Scholar
• Ghosal A, Barecki-Roach M, Ramanathan R, Characterization of the in vitro human liver cytochrome P450 (CYP) mediated metabolism and inhibition potential of vicriviroc. Retrovirology 2005;2(Suppl 1): abstract P116
   Google Scholar
• Ramanathan R, Zhong R, Alvarez N, Comparative metabolism and excretion of a novel CCR5 receptor antagonist, Sch 417690 (vicriviroc), in human, monkey and rat. Drug Metab Rev 2005;37:725-6
   Google Scholar
• Ikezoe T, Hisatake Y, Takeuchi T, HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004;64:7426-31
   PubMed Web of Science ®Google Scholar
• Seiberling M, Kraan M, Keung A, Similar increase in vicriviroc exposure with co-administration of varying doses of ritonavir in healthy volunteers [abstract TUPE3.1B06]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
   Google Scholar
• Sansone A, Keung A, Tetteh E, Vicriviroc (VCV) pharmacokinetics (PK): lack of impact of ritonavir (RTV)-boosted protease inhibitors (PI) [abstract TUPE0074]. XVI International AIDS Conference; 2006
   Google Scholar
• Kasserra C, Sansone-Parsons A, Keung A, Vicriviroc pharmacokinetic parameters are unchanged when co-administered with darunavir in a ritonavir containing regimen [abstract P35]. 9th annual International Workshop on Clinical Pharmacology of HIV Therapy; 2008
   Google Scholar
• Saltzman M, Rosenberg M, Kraan M, Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir [abstract TUPE3.1B05]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
   Google Scholar
• Guillaume M, Kraan M, Keung A, The pharmacokinetics of SCH 417690 when administered alone and in combination with lamivudine/zidovudine [abstract TUPE3.1B03]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
   Google Scholar
• Guillaume M, Kraan M, Soni P, Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir [abstract TUPE3.1B09]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
   Google Scholar
• Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009;48:211-41
   PubMed Web of Science ®Google Scholar
• Saltzman M, Rosenberg M, Kraan M, Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers [abstract TUPE3.1B08]. 3rd IAS Conference on HIV Pathogenesis and Treatment; 2005
   Google Scholar
• Kasserra C, Adamczyk R, Li J, The effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics [abstract TUPE0043]. XVII International AIDS Conference; 2008
   Google Scholar
• Kasserra C, O'Mara E, Lisbon E. Assessment of pharmacokinetic and safety interactions between vicriviroc and CYP3A4 substrates, inhibitors, and inducers [abstract H-230]. 49th ICAAC 2009
   Google Scholar
• Landovitz RJ, Angel JB, Hoffmann C, Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008;198:1113-22
   PubMed Web of Science ®Google Scholar
• McNicholas P, Wei Y, Whitcomb J, Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J Infect Dis 2010;201:1470-80
   PubMed Web of Science ®Google Scholar
• Gulick RM, Su Z, Flexner C, Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007;196:304-12
   PubMed Web of Science ®Google Scholar
• Su Z, Gulick RM, Krambrink A, Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 2009;200:1724-8
   PubMed Web of Science ®Google Scholar
• Tsibris AM, Korber B, Arnaout R, Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009;4:e5683
   PubMed Web of Science ®Google Scholar
• Tsibris AM, Sagar M, Gulick RM, In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008;82:8210-14
   PubMed Web of Science ®Google Scholar
• Suleiman J, Zingman BS, Diaz RS, Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010;201(4):590-9
   PubMed Web of Science ®Google Scholar
• Gathe J, Diaz R, Fatkenheuer G, Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone [abstract 54LB]. 17th CROI 2010
   Google Scholar
• Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naive Subjects (Study P04875AM5) Available from: http://clinicaltrials.gov/ct2/show/NCT00551018 [Last accessed 26 April 2010]
   Google Scholar
• Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009;4:118-24
   PubMedGoogle Scholar
• O'Mara E, Kasserra C, Huddlestone JR, The effect of vicriviroc on the QT/QTc interval and central nervous system in healthy subjects. Antimicrob Agents Chemother 2010: published online 29 March 2010, doi:10.1128/AAC.01447-09
   PubMed Web of Science ®Google Scholar
• Gulick R, Haas D, Collier AC, Two-year follow-up of treatment-experienced patients on vicriviroc (VCV) [abstract H-1030]. 47th Interscience ICAAC 2007
   Google Scholar
• Dunkle LM, Greaves W, McCarthy MC, Long term safety of vicriviroc [abstract H-1269]. 48th ICAAC 2008
   Google Scholar
• Fatkenheuer G, Hoffmann C, Slim J, Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable. J Acquir Immune Defic Syndr 2010;53:78-85
   PubMed Web of Science ®Google Scholar
• Kasserra C, Sansone-Parsons A, Keung A, Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen. Clin Pharmacokinet 2010: published online 1 June 2010, doi:10.2165/11319470-000000000-00000
   PubMed Web of Science ®Google Scholar
• Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected Antiretroviral Treatment Experienced Children and Adolescents. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00766597 [Last accessed 14 July 2010]
   Google Scholar
• UPDATE 2-Merck HIV drug from Schering merger fails trails. Available from: http://www.reuters.com/article/idUSN2017965820100120 [Last accessed 26 April 2010]
   Google Scholar
• Hunt PW, Brenchley J, Sinclair E, Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008;197(1):126-33
   PubMed Web of Science ®Google Scholar
• Hunt PW, Martin JN, Sinclair E, T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187(10):1534-43
   PubMed Web of Science ®Google Scholar